Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Pramoxine

What is Pramoxine?

CAS No: 140-65-8

Pramocaine (also known as pramoxine or pramoxine HCI) is a topical anesthetic and antipruritic. It is used for many dermatological and anorectal/anogenital conditions including minor cuts/burns, insect bites, hives/rashes due to poison ivy exposure, hemorrhoids and other anorectal/anogenital disorders. Pramocaine is available by itself and in combination with other medications in various topical preparations. It works by preventing ionic fluctuations needed for neuron membrane depolarization and action potential propagation.

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Pramoxine is a pharmaceutical substance or chemical compound identified by this name. Its pharmacological properties and the available substance-specific evidence may be relevant when evaluating occupational exposure and potential product carryover. A formal assessment should distinguish established information from assumptions and document the rationale for any recommended exposure limits or control measures.

A toxicological assessment characterizes the potential health hazards of (2R,4S)-2-Ethyl-6-(Trifluoromethyl)-1,2,3,4-Tetrahydroquinoline-4-Amine using the available data. It supports scientifically justified exposure limits, helps manufacturers choose proportionate handling and containment measures, and gives a documented basis for protecting workers and preventing cross-contamination in shared facilities.

The physical form in which Pramoxine is handled, such as a powder, granulated material, or solution, can influence how exposure may occur during routine operations. The assessment should consider the actual process, opportunities for dust, droplets, or aerosols, and the effectiveness of containment and work practices. Physical form does not independently determine toxicity, but it can affect exposure control decisions.

For Pramoxine, therapeutic dose information may provide context when it is relevant and reliable, but it is not automatically a suitable basis for a PDE, ADE, or OEL. The assessment must evaluate toxicological endpoints, dose-response evidence, route, and intended application. Any use of clinical or pharmacological information should be justified and considered alongside the full evidence package.

Where relevant to Pramoxine, available genotoxicity information should be reviewed as part of the overall assessment. If the substance falls within the scope of ICH M7, its principles may inform the evaluation of mutagenic impurities or compounds, as applicable. The approach depends on the substance’s role and evidence; no mutagenic classification should be assumed without adequate supporting data.

Not necessarily. A PDE or ADE is derived for a defined route of exposure, often oral for carryover into the next product. Extrapolating to inhalation or dermal exposure needs scientific justification, so the report should state the route, scope, and assumptions behind the value.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

A toxicological assessment of Pramoxine organizes the available evidence about potential health hazards and uncertainty. Its conclusions can support scientifically justified exposure limits and proportionate controls for manufacturing, sampling, transfer, and cleaning. The assessment should distinguish established findings from assumptions and identify data gaps that may affect confidence in the recommendations.

For Pramoxine, uncertainty factors may address differences between test species and humans, variation among individuals, study duration, data quality, and other limitations in the evidence. The choice and magnitude of each factor should be scientifically justified rather than selected automatically. Clear documentation allows reviewers to understand how the point of departure supports the final health-based exposure limit.

Published information for Pramoxine may not cover every endpoint needed for a complete assessment. A risk-based evaluation can consider reliable data that are available, relevant information from structurally related substances, and scientifically justified structure-based approaches where appropriate. Any extrapolation, uncertainty, and data gap should be documented, and conclusions should not imply certainty beyond the supporting evidence.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add (2R,4S)-2-Ethyl-6-(Trifluoromethyl)-1,2,3,4-Tetrahydroquinoline-4-Amine to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo